Evidence map›Paper›PMID 29147757›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2018

Prospective evaluation of CO

Carlo Alberto Cutolo, Alessandro Bagnis, Riccardo Scotto, Chiara Bonzano, Carlo Enrico Traverso

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. COFrontiers in medicine · 2024
    Article
  2. An overview and update of COExperimental and therapeutic medicine · 2023
    Review
  3. Clinical application of the COFrontiers in medicine · 2022
    Article
  4. Article
  5. COJournal of ophthalmology · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Carlo Alberto CutoloClinica Oculistica Università di Genova DiNOGMI - Ospedale Policlinico San Martino, Viale Benedetto XV, 5, 16136, Genoa, Italy. cacutolo@gmail.com.ORCID http://orcid.org/0000-0002-2433-0704
Alessandro BagnisClinica Oculistica Università di Genova DiNOGMI - Ospedale Policlinico San Martino, Viale Benedetto XV, 5, 16136, Genoa, Italy.
Riccardo ScottoClinica Oculistica Università di Genova DiNOGMI - Ospedale Policlinico San Martino, Viale Benedetto XV, 5, 16136, Genoa, Italy.
Chiara BonzanoClinica Oculistica Università di Genova DiNOGMI - Ospedale Policlinico San Martino, Viale Benedetto XV, 5, 16136, Genoa, Italy.
Carlo Enrico TraversoClinica Oculistica Università di Genova DiNOGMI - Ospedale Policlinico San Martino, Viale Benedetto XV, 5, 16136, Genoa, Italy.
Ospedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur purpose was to evaluate the clinical safety and efficacy of CO

methodsThis was a prospective, uncontrolled, interventional case series. All subjects underwent CLASS procedure by a single surgeon. After the dissection of a partial thickness scleral flap, topical MMC 0.2 mg/ml was applied to the sclera and the conjunctiva for 3 min. The CO

resultsTwenty-one eyes of 21 patients underwent the CLASS procedure. Thirteen were primary OAG (62%), two normal pressure glaucoma (10%), three exfoliative glaucoma (14%) and three others secondary OAG. With a mean (SD) follow-up of 15.3 (5.9) months, the IOP changed from 25.4 (6.7) mmHg at baseline to 10.9 (3.4) mmHg al the last visit. Mean reduction of IOP was -14.5 mmHg (95% CI, -17.7 to -11.2, P < 0.001). The median (IQR) number of IOP-lowering medication decreased from 3 (3-3) at baseline to 1 (0-1) at the last visit (P < 0.001). Visual acuity did not change significantly. Adverse events: five eyes (24%) developed iris adhesion to the filtration area that was successfully managed with office-based procedures. In one case (5%), CLASS was converted to trabeculectomy due to intraoperative perforation of the ablated area. There was one case of hypotony maculopathy successfully treated with placement of additional transconjunctival scleral flap sutures.

conclusionsThe CLASS procedure with MMC is clinically safe and effective maintaining a large reduction in IOP and in the number of IOP-lowering medications with a mean follow-up of 15 months. Iris adhesion at the filtrating area warrants further evaluation and possibly reflects the surgeon's learning curve.

Indexed as

AgedAntibiotics, AntineoplasticFemaleFollow-Up StudiesGlaucoma, Open-AngleHumansIncidenceIntraocular PressureItalyLasers, GasLaser TherapyMaleMitomycinPostoperative ComplicationsProspective StudiesScleraAntibiotics, AntineoplasticMitomycinCO2 laserDeep sclerectomyGlaucoma surgeryLaser

Identifiers

PMID29147757
OpenAlexW2770888305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.